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012.08.00Abstract Patients and methods: The study included 30 patients with RA diagnosed according to
the 2010 ACR-EULAR classiﬁcation criteria for RA and 15 healthy controls. Patients were
included if they were above 18 years and fulﬁlled a score P6 over 10 of the 2010 ACR-EULAR
classiﬁcation criteria for RA. Disease activity was assessed using 28 joint disease activity score
(DAS28), erythrocytes sedimentation rate (ESR), C-reactive protein (CRP). Fatigue was assessed
with the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ)
and serum IL-6 level was measured in patients and controls.
Results: The BRAF-MDQ was signiﬁcantly higher among patients (mean = 50.6 ± 15.2) than
controls (mean = 7.8 ± 3.7) (p< 0.001). Patients’ mean IL-6 serum level was 35.05 ± 21.23 pg/ml
and 4.72 ± 3.09 pg/ml among control subjects (p< 0.001). DAS 28 ranged between 4.33 and 7.67,
mean 1st hour ESR was 43.57 mm and CRP was positive in 76.7% of patients. Signiﬁcant correla-
tions were found between BRAF-MDQ score and serum IL-6 level (r= 0.947, p< 0.001), ESR
(r= 0.509, p< 0.001) as well as CRP positivity (r= 0.411, p= 0.005) in RA patients. Serum
IL-6 level correlated with ESR (r= 0.463, p< 0.001) and CRP (r= 0.376, p= 0.01) among
patients.
Conclusion: Fatigue is a common symptom and scores higher among RA patients than healthy
controls and should be measured in all RA patients with simple fatigue questionnaires matching
with different cultures. Fatigue becomes more prominent as serum IL-6 level increases indepen-
dently of the disease duration and activity.
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41. Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory autoim-
mune disorder affecting most commonly middle-aged women.
It is characterized by inﬂammation of the synovium, whichuction and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
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juxta-articular bone. It is often accompanied by systemic man-
ifestations such as anemia, fatigue and osteoporosis [1]. Fati-
gue is a subjective feeling of low vitality that disrupts daily
functioning, especially prevalent in chronic inﬂammatory dis-
orders such as rheumatoid arthritis [2]. Unlike normal tired-
ness, fatigue is chronic, typically not related to overexertion
and poorly relieved by rest. People with RA consider fatigue
to be an important physical and cognitive symptom that is
overwhelming, uncontrollable and unpredictable that affects
every aspect of life [3]. Rheumatoid arthritis fatigue is complex
and multicausal. Pain, stress, depression, inﬂammation, meta-
bolic factors, medications and disability are likely to contrib-
ute to the development of RA fatigue in varying degrees at
different time [2]. Little attention has been paid by health pro-
fessional teams to the multidimensional nature of RA related
fatigue. International consensus has recommended that RA fa-
tigue should now be measured in RA studies alongside the core
set, using a validated instrument [3].
In RA, the cytokine network is complex with numerous
cytokines present both in blood and in synovial joints [1,4].
Elevation in pro-inﬂammatory cytokine levels is capable of
promoting fatigue in RA. Also, the hypothalamic pituitary
adrenal (HPA) axis abnormality has been linked to the occur-
rence of RA fatigue [3]. Interleukin 6 (IL-6) is one of the cyto-
kines which play a signiﬁcant role in RA pathogenesis and
promotion of fatigue [1,5]. This work is aimed at the assess-
ment of occurrence and level of fatigue and its relation to
IL-6 serum level in RA patients.
2. Patients and methods
Thirty RA patients diagnosed according to the 2010 American
College of Rheumatology/European League Against Rheuma-
tism (ACR-EULAR) classiﬁcation criteria for RA [6] were en-
rolled in the study. Patients were included if they were more
than 18 years and fulﬁlled a score P6 over 10 of the 2010
ACR-EULAR classiﬁcation criteria for RA. Patients with
other systemic inﬂammatory rheumatic diseases, ﬁbromyalgia
syndrome and other causes of fatigue as anemia, hepatic dis-
eases, kidney diseases, diabetes mellitus, cardiovascular dis-
eases, psychiatric disorders and malignancy were excluded.
Fifteen healthy age and gender matched controls were enrolled
in the study. An informed consent has been taken from all pa-
tients and control subjects before the beginning of the study
which was approved by the local Ethics Committee.
Demographic data anddisease history regarding onset, dura-
tion, course, progression and medications received were ob-
tained from all patients. A thorough clinical examination of
the musculoskeletal system was carried out. Disease activity
was assessed using the 28 joint disease activity score (DAS28)
which was performed bilaterally on the shoulders, the elbows,
the wrists, themetacarpophalangeals, the proximal interphalan-
geals and the knee joints. Tenderness and swelling were assessed
separately in each joint. Calculation of DAS28 score entailed:
(1) Tender joints count (TJC); it was scored on a 0–1 scale:
0 = no tenderness, 1 = tenderness. The individual joint scores
were summed. (2) The swollen joint count (SJC); it was assessed
also on a 0–1 scale: 0 = no swelling, 1 = swelling. Then the
individual joint scores were summed [7]. (3) Erythrocyte sedi-
mentation rate (ESR). (4) Patient’s assessment of his/her generalhealth (GH) on a visual analog scale (VAS) (0–100 mm; where
‘‘0’’ represents good general condition and ‘‘100’’ worst condi-
tion). The DAS 28 formula ‘‘DAS28= 0.56
p
(TJC)
+ 0.28
p
(SJC) + 0.70 ln (ESR) + 0.014 (GH)’’ was used.
DAS28 is a continuous index ranging from 0 to 9.4. A DAS
28 6 3.2 = low disease activity, DAS 28> 3.2 to65.1 = mod-
erate disease activity, DAS28 > 5.1 = high disease activity. A
commonly used cutoff point for remission in DAS28 is < 2.6
[8]. Each patient and control subject was assessed with the Bris-
tolRheumatoidArthritis FatigueMulti-Dimensional Question-
naire (BRAF-MDQ) [9]. The 20 items BRAF-MDQ has 4
distinct dimensions: the physical, living, cognition and emotion
dimensions. The physical dimension contains a numerical rating
scale and questions on frequency and duration of fatigue, but
the response options to all questions of other dimensions are
scored as 0–3 (where 0 = not at all, 1 = a little, 2 = quite a
bit, and 3 = very much). Simple summation yields a global
BRAF-MDQ score of 0–70 (with higher scores indicating worse
fatigue), whereas the score for each dimension is different due to
the varied number of questions (0–22 for physical, 0–21 for liv-
ing, 0–15 for cognition, and 0–12 for emotion). Laboratory
investigations were carried out for each patient and control sub-
ject and included ESR using the standard Westergren method
[10], C-reactive protein (CRP) using the nephelometer assay
[11] and serum IL-6 level using the enzyme-linked immunosor-
bent assay (ELISA) technique (AviBion Human IL-6 ELISA
Kit, Orgenium Laboratories, Finland). Serum concentration of
IL-6 was determined based on a standard concentration curve
[12]. Statistical analysis was done using the software Statistical
Package for the Social Sciences (SPSS) version 17.0. All of the
descriptive variables were expressed as the mean ± standard
deviation (SD). For comparison between the two groups, Stu-
dent’s t testwas used.Chi-Square test, Pearson’s correlation coef-
ﬁcient and multiple linear regression were used to assess the
association and correlation between variables. A probability (p)
value 60.05 was considered statistically signiﬁcant for all tests.
3. Results
The study included 27 women (90%) and 3 men (10%) in pa-
tients group and 13 women (86.6%) and 2 men (13.3%) in the
control group. Patients’ age ranged between 20 and 64 years
(mean ± SD: 45.23 ± 12.34) and the mean age of the control
group was 41.22 ± 9.13. The disease duration of RA ranged
between 3 months and 360 months (88.5 ± 76.1).
All studied patients had high BRAF-MDQ scores which was
signiﬁcantly higher in the studied RA patients than in the con-
trol group (p= 0.01). The mean BRAF-MDQ score was
50.6 ± 15.2 among patients. While mean BRAF-MDQ score
was 7.8 ± 3.7 among controls (Table 1). The histogram repre-
sentation of BRAF-MDQ score in the studiedRApatients dem-
onstrated that the score had 2 peaks, one at 50 and another at 70;
meanwhile, in the control group, the BRAF-MDQ score aggre-
gated between 0 and 20 and peaking near the 10 score point
(Fig. 1). The DAS28 score in RA patients ranged between 4.3
and 7.6, with a mean score of 5.3 ± 0.6.
The 1st hour ESR ranged between 24 and 113 mm, with a
mean level of 43.5 ± 25.6 in RA patients, while in the controls
it ranged between 5 and 35 mm, with a mean level of 15.8 ± 8.3
(p< 0.001). The percentage of patients who had positive CRP
was signiﬁcantly higher (76.7%) than those with negative CRP
Figure 2 The correlation between the Bristol Rheumatoid
Arthritis Fatigue Multi-Dimensional Questionnaire score and
interleukin-6 serum level in the studied RA patients.
Figure 1 Graphic representation of the distribution of the
BRAF-MDQ score among studied rheumatoid arthritis patients
and control groups.
Table 1 Comparison between patients and control group regarding the BRAF-MDQ score and serum IL-6 level.
Patients ‘‘n= 30’’ mean ± SD Control ‘‘n= 15’’ mean ± SD t p
BRAF-MDQ 50.6 ± 15.2 7.8 ± 3.7 10.6 0.001*
Serum IL-6 level (pg/ml) 35.0 ± 21.2 4.7 ± 3.0 5.47 0.001*
P* is signiﬁcant at 60.05.
Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF-MDQ).
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tients) had positive CRP compared to 3 control subjects
(20%) (p< 0.001).
Serum IL-6 concentration was signiﬁcantly elevated in RA
patients compared to healthy controls (p< 0.001). Serum IL-6
concentrations in the patients group ranged between 5 and
130 pg/ml, with a mean of 35.0 ± 21.2, while in the controls
it ranged between 1 and 10 pg/ml, with a mean of 4.7 ± 3.0
(Table 1).
Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional
Questionnaire correlated with serum IL-6 levels of RA patients
(r= 0.947, p< 0.001) (ﬁg. 2). Similarly, BRAF-MDQ score of
RA patients correlated with the ESR values (r= 0.509,
p< 0.001) and CRP (r= 0.411, p= 0.005), where patients
with positive CRP had higher BRAF-MDQ scores
(49.95 ± 16.24) and whose CRPwas negative had lower fatigue
scores (52.85 ± 12.03). Therewere no signiﬁcant correlation be-
tween BRAF-MDQ score and DAS28 score (r= 0.174,
p= 0.358). No signiﬁcant relationship was found between
BRAF-MDQ score and age, gender of RA patients or their dis-
ease duration (p> 0.05).
Although there was no signiﬁcant relationship between IL-
6 cytokine level and DAS28 score, serum IL-6 levels showed a
signiﬁcant correlation with the ESR (r= 0.463, p< 0.001)
and CRP of RA patients (r= 0.376, p= 0.01), as patients
with positive CRP had higher IL-6 levels and vice versa
(35.07 ± 24.87 and 35.60 ± 7.77 pg/ml respectively).
4. Discussion
Rheumatoid arthritis fatigue is complex and multicausal. It
results from the interaction between disease, cognitive, behav-ioral factors and personal life issues and so its assessment and
management is complex [13]. The current results showed that
RA patients had signiﬁcantly higher fatigue scores and ele-
vated serum IL-6 levels compared to healthy controls. Bristol
Rheumatoid Arthritis Fatigue Multi-Dimensional Question-
naire correlated signiﬁcantly with serum IL-6 levels. Systemic
actions of IL-6 include; stimulation of production of acute-
phase proteins, induction of anemia, and impairment of
HPA axis [14]. Hypothalamic–pituitary–adrenal axis abnor-
mality has been linked to the development of fatigue in many
diseases [15]. In the central nervous system, IL-6 can modulate
the HPA axis. Following IL-6 administration, healthy volun-
teers recorded increased fatigue, inactivity, lack of concentra-
tion and altered sleep architecture and these effects were
found to correspond with the HPA axis disturbed function
[4]. In this study, the correlations between fatigue scores,
ESR level and CRP positivity could be due to the high disease
activity of the studied patients. Similarly, Wirnsberger et al.
[16] reported that higher fatigue scores of RA patients were
linked to high CRP level. The present study found no correla-
tion between DAS28 score and fatigue. Failure to demonstrate
such correlation is not to downplay the importance of fatigue
in RA but it appears that psychosocial aspects like depression,
self-efﬁcacy and lack of social support might be the most
important variables in explaining fatigue [17]. Some studies re-
ported correlation between fatigue and patient’s assessment of
global health component of the DAS28 score [17–19]. This
observation indicates that physician and laboratory compo-
nents of the DAS28 contribute minimally to fatigue scores.
Further, RA and OA patients in the clinical and research
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contrary, other studies found a signiﬁcant correlation between
fatigue and disease activity and emphasized that lack of fatigue
was a feature of clinical remission in RA [20,21]. In the current
study, fatigue did not correlate with age or disease duration of
the studied patients. Similarly, Pollard et al. [18] have reported
no signiﬁcant correlation between fatigue severity and disease
duration or age. They related their ﬁndings to the likelihood of
central origin of RA fatigue rather than the importance of
peripheral features like muscle mass which decreased with
age and disease duration. While Nikolaus et al. [22] stated that
younger women with multiple roles experience more fatigue
and after retirement, people have fewer roles and less expecta-
tions from others, so older people might be able to cope with
fatigue more easily. Also, fatigue score did not correlate with
gender of the studied RA patients. However, fewer men than
women participated in this study is considered as one of the
study limitations which may reduce the generalizability of
the results. On the contrary, Huyser et al. [23] reported that
the best predictor of fatigue was being a female. In another
study, Nikolaus et al. [22] reported that women experienced
more negative emotions and consequently more fatigue com-
pared to men. According to Nikolaus et al., negative emotions
related to fatigue might occur when personal abilities do not
meet with one’s expectations and wishes, and might be wors-
ened by external demands related to multiple roles.
The current study showed a correlation between serum IL-6
levels and ESR level as well as CRP positivity. This is consistent
with the known function of IL-6 as a stimulator of hepatic syn-
thesis of acute phase reactants [24]. However, no signiﬁcant
relationship between serum IL-6 levels and the DAS28 score
was found. This result agreed with Chung et al. [25], who ex-
plained this ﬁnding by the difference of involvement of the
IL-6 family cytokines in the local and systemic reactions; in
the synovium and serum. These cytokines were found to be in-
volved mainly in the local reaction and higher levels are within
synovial ﬂuid than in serum so levels of circulating, peripherally
produced cytokines may not reﬂect the local situation in the
joints. This may be the reason that the serum concentrations
of cytokines do not signiﬁcantly correlate with the disease activ-
ity. In this study, serum IL-6 did not correlate with age, gender
or disease duration. Similarly, Madhok et al. [26] conﬁrmed
that serum IL-6 values are increased in RA patients and are
independent of age, patient’s gender and duration of RA.
The low number of patients and controls is one of the lim-
itations of this study. Also, the low number of men included in
patient and control groups is another limitation. It is recom-
mended to extend this study in future work to include more pa-
tients; particularly men to provide more solid conclusions
regarding correlation between fatigue and gender in RA.
In conclusion, fatigue is a common symptom and scores
higher among RA patients than healthy controls. Thus, its
evaluation and treatment should be incorporated in the man-
agement of RA. Fatigue becomes more prominent as serum
IL-6 level increases independently of the disease duration
and activity.
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